Literature DB >> 24200974

Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review.

Li Wei Ang1, Jeffery Cutter2, Lyn James3, Kee Tai Goh4.   

Abstract

We undertook a national hepatitis B seroprevalence study to assess the seroprevalence of hepatitis B virus (HBV) markers in the adult population in Singapore in 2010 and make comparisons with the seroprevalence in 1998 and 2004. The study involved residual sera from national health surveys conducted every six years since 1998. The tests for HBV markers were carried out using commercial chemiluminescent microparticle immunoassay. In 2010, the prevalence of hepatitis B surface antigen (HBsAg) among 3293 Singapore residents aged 18-79 years was 3.6% (95% confidence interval [CI] 2.9-4.2%). Hepatitis B e antigen (HBeAg) was detected in 4.2% of those who were HBsAg positive. About 22.5% (95% CI 21.1-23.9%) were positive for antibody to hepatitis B core antigen (anti-HBc). The overall population immunity to HBV, as determined by antibody to hepatitis B surface antigen (anti-HBs)≥ 10 mIU/mL, was 43.9% (95% CI 42.2-45.6%). Among young adults below 30 years of age, HBsAg prevalence (1.1%) was half that in 1998 and 2004, and in those positive for HBsAg, none was positive for HBeAg in 2010, compared to 20.8% in 1998 and 15.8% in 2004. In this age group, anti-HBc prevalence also decreased significantly from 22.1% in 2004 to 4.4% in 2010, while anti-HBs (≥ 10 mIU/mL) prevalence increased significantly from 27.9% in 1998 to 43.3% in 2010 (p<0.001). The national childhood HBV immunisation and catch-up programmes implemented in 1987 and 2001-2004, respectively, had a significant impact in reducing HBV infection and in raising the immunity of the adult population 18-29 years of age.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatitis B virus markers; Immunisation; National seroprevalence survey

Mesh:

Substances:

Year:  2013        PMID: 24200974     DOI: 10.1016/j.vaccine.2013.10.057

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

Review 1.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

Review 2.  Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability.

Authors:  Katherine A McGlynn; Jessica L Petrick; W Thomas London
Journal:  Clin Liver Dis       Date:  2015-02-26       Impact factor: 6.126

Review 3.  Prevention of hepatocellular carcinoma and monitoring of high-risk patients.

Authors:  Eda Kaya; Guillermo Daniel Mazzolini; Yusuf Yilmaz; Ali Canbay
Journal:  Hepatol Forum       Date:  2022-01-09

Review 4.  Hepatitis B virus burden in developing countries.

Authors:  Rosa Zampino; Adriana Boemio; Caterina Sagnelli; Loredana Alessio; Luigi Elio Adinolfi; Evangelista Sagnelli; Nicola Coppola
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

5.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

6.  Impact and long-term protection of hepatitis B vaccination: 17 years after universal hepatitis B vaccination in Tunisia.

Authors:  H Chaouch; W Hachfi; I Fodha; O Kallala; S Saadi; A Bousaadia; F Lazrag; I Bougmiza; M Aouni; A Trabelsi; E Ben Jazia; A Letaief
Journal:  Epidemiol Infect       Date:  2016-08-18       Impact factor: 4.434

7.  Public awareness and knowledge of liver health and diseases in Singapore.

Authors:  Chee-Kiat Tan; George Boon-Bee Goh; Jin Youn; Jacques Chak-Kwan Yu; Shikha Singh
Journal:  J Gastroenterol Hepatol       Date:  2021-03-30       Impact factor: 4.369

8.  International trends in primary liver cancer incidence from 1973 to 2007.

Authors:  Yue Zhang; Jian-Song Ren; Ju-Fang Shi; Ni Li; Yu-Ting Wang; Chunfeng Qu; Yawei Zhang; Min Dai
Journal:  BMC Cancer       Date:  2015-03-04       Impact factor: 4.430

9.  Deciphering the epidemiology of hepatocellular carcinoma through the passage of time: A study of 1,401 patients across 3 decades.

Authors:  George Boon-Bee Goh; James Weiquan Li; Pik-Eu Chang; Khuan-Yew Chow; Chee-Kiat Tan
Journal:  Hepatol Commun       Date:  2017-06-14

10.  Cost Effectiveness of Universal Hepatitis B Virus Screening in Patients Beginning Chemotherapy for Sarcomas or GI Stromal Tumors.

Authors:  Glorijoy Tan; Ke Zhou; Chee Hian Tan; David B Matchar; Mohamad Farid; Richard Quek; Joanne Ngeow
Journal:  J Glob Oncol       Date:  2016-02-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.